PSA-stratified performance of 18F-and 68Ga-PSMA PET in patients with biochemical recurrence of prostate cancer

Journal of Nuclear Medicine

Volumn 58, Issue 6, 2017, Pages 947-952

  Dietlein, Felix ^a   Kobe, Carsten ^a   Neubauer, Stephan ^b   Schmidt, Matthias ^a   Stockter, Simone ^a   Fischer, Thomas ^a   Schomäcker, Klaus ^a   Heidenreich, Axel ^a   Zlatopolskiy, Boris D ^a   Neumaier, Bernd ^a   Drzezga, Alexander ^a   Dietlein, Markus ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Klinik am Ring   (Germany)

Author keywords

18F DCFPyL; 68Ga PSMA HBED CC; Biochemical recurrence; Prostate cancer; PSMA ligands

Indexed keywords

FLUORINE 2 [3 [1 CARBOXY 5 (6 FLUORO PYRIDINE 3 CARBONYL)AMINO PENTYL] UREIDO] PENTANEDIOIC ACID F 18; GALLIUM PROSTATE SPECIFIC MEMBRANE ANTIGEN HBED CC GA 68; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; 2-(3-(1-CARBOXY-5-((6-FLUOROPYRIDINE-3-CARBONYL)AMINO)PENTYL)UREIDO)PENTANEDIOIC ACID; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; LYSINE; ORGANOMETALLIC COMPOUND; TUMOR MARKER; UREA;

AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER RADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIOSENSITIVITY; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; GERMANY; PREVALENCE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

AGED; BIOMARKERS, TUMOR; GERMANY; HUMANS; KALLIKREINS; LYSINE; MALE; NEOPLASM RECURRENCE, LOCAL; ORGANOMETALLIC COMPOUNDS; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UREA;

EID: 85018991765     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.185538     Document Type: Article

References (21)

1. Freedland SJ, Rumble RB, Finelli A, et al. Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2014;32:3892-3898.
2. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15:167-172.
3. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
4. Ceci F, Uprimny C, Nilica B, et al. 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284-1294.
5. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
6. van Leeuwen PJ, Stricker P, Hruby G, et al. 68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117:732-739.
7. Bluemel C, Krebs M, Polat B, et al. 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT. Clin Nucl Med. 2016;41:515-521.
8. Afshar-Oromieh A, Hetzheim H, Kubler W, et al. Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611-1620.
9. Derlin T, Weiberg D, von Klot C, et al. 68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol. 2016;26:4345-4353.
10. Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMAbased PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645-7653.
11. Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [18F]DCFPyL for prostatespecific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565-574.
12. Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [18F]DCFPyL and [68Ga] Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575-584.
13. Budäus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69:393-396.
14. Eiber M, Weirich G, Holzapfel K, et al. Simultaneous Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70:829-836.
15. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195:1436-1443.
16. Herlemann A, Wenter V, Kretschmer A, et al. Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 2016;70:553-557.
17. Roesch F. Maturation of a key resource: the germanium-68/gallium-68 generator: development and new insights. Curr Radiopharm. 2012;5:202-211.
18. Alva-Sánchez H, Quintana-Bautista C, Martinez-Davalos A, Avila-Rodriguez MA, Rodriguez-Villafuerte M. Positron range in tissue-equivalent materials: experimental microPET studies. Phys Med Biol. 2016;61:6307-6321.
19. Eder M, Schäfer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688-697.
20. Schäfer M, Bauder-Wust U, Leotta K, et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012;2:23.
21. Armstrong IS, Kelly MD, Williams HA, Matthews JC. Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies. EJNMMI Phys. 2014;1:99.